Cetera Investment Advisers’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
UCFA
GKWIM
YIA
Cetera Investment Advisers's PBE Position: Q2 2026 in Review
Cetera Investment Advisers increased its Invesco Biotechnology & Genome ETF (PBE) stake by 11% in Q2 2026, buying an estimated $216K and bringing the position to 25,760 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.
Cetera Investment Advisers first reported a position in PBE in Q4 2022 and has held it in 15 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.
- Cetera Investment Advisers held 25,760 shares of Invesco Biotechnology & Genome ETF worth $2.31M as of Q2 2026.
- Cetera Investment Advisers bought 2,621 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $216K.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #2277 holding.
- Cetera Investment Advisers first reported a position in Invesco Biotechnology & Genome ETF in Q4 2022 and has held it in 15 quarters since.
- 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.
Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.